{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-22-000055","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.605190+00:00","generated_at":"2026-06-24T01:22:21.283460+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pacira reports July 2022 net product sales of $50.2M; EXPAREL daily sales up 5% YoY","bullets":["Preliminary unaudited net product sales for July 2022: $50.2M total ($40.9M EXPAREL, $8.2M ZILRETTA, $1.1M iovera°).","EXPAREL net sales flat vs. July 2021 at $40.9M, but average daily sales up 5% on 20 vs. 21 selling days.","ZILRETTA sales of $8.2M reflect continued early-stage growth; iovera° sales $1.1M vs. $1.0M prior year.","CEO cites expanding EXPAREL adoption; Phase 3 lower extremity nerve block results expected in Q3 and Q4 2022.","No FY2022 revenue or gross margin guidance provided due to ongoing COVID-19 and labor uncertainty."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-22-000055","json":"https://secwatch.observer/filing/0001396814-22-000055.json","markdown":"https://secwatch.observer/filing/0001396814-22-000055.md","text":"https://secwatch.observer/filing/0001396814-22-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681422000055/0001396814-22-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681422000055/pcrx-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:22:21.283460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}